Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IWOT
2018-003539-31Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of temozolomide in astrocytoma, diffuse astrocytoma, anaplastic astrocytoma (AA) and 1 more (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Next intervention free survival. Started May 2019; status: terminated.
02
Drugs
temozolomide
03
Conditions
astrocytomadiffuse astrocytomaanaplastic astrocytoma (AA)glioma
Beyond the preview
Go deeper on 2018-003539-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003539-31.